Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Bayesian Optimal Phase II Design for Randomized Clinical Trials

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Optimal Bayesian predictive probability for delayed response in single-arm clinical trials with binary efficacy outcome

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

MIDAS: a Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents

Bayesian Optimal Interval Designs for Phase I Clinical Trials

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Incorporating Historical Information to Improve Phase I Clinical Trials

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.